Robert B. Warner

1.3k citations

19 papers · 873 indexed · h-index 10

Impact in

Organic Chemistry top 5%
- Synthesis and biological activity
- Multicomponent Synthesis of Heterocycles
- Click Chemistry and Applications
- Synthesis and Biological Evaluation
- Synthesis and Characterization of Heterocyclic Compounds
Toxicology top 10%

Papers in

Cardiology and Cardiovascular Medicine 5
- Renin-Angiotensin System Studies 3
Organic Chemistry 5
- Synthesis and biological activity 2
- Click Chemistry and Applications 2

Co-authors: Saul H. Rosenberg Hing L. Sham R.B. Credo Qun Li David J. Frost Kenneth J. Barr Keith W. Woods Jang Y. Lee
Journals: Pharmacology (3 papers)Bioorganic & Medicinal Chemistry Letters (3 papers)Journal of Pharmacology and Experimental Therapeutics (2 papers)Journal of Medicinal Chemistry (2 papers)Life Sciences (1 paper)
Partner nations: United States United Kingdom

In The Last Decade

Robert B. Warner

19 papers receiving 847 citations

Peers

Countries citing papers authored by Robert B. Warner

Since Specialization

Citations

This map shows the geographic impact of Robert B. Warner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert B. Warner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert B. Warner more than expected).

Fields of papers citing papers by Robert B. Warner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert B. Warner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert B. Warner. The network helps show where Robert B. Warner may publish in the future.

Co-authors

The 25 scholars most cited alongside Robert B. Warner, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Robert B. Warner Line = papers co-authored together Robert B. Warner links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work
1	Influence of Bcl-2 Family Members on the Cellular Response of Small-Cell Lung Cancer Cell Lines to ABT-737 Cancer Research ·Stephen K. Tahir, Xiufen Yang, Mark G. Anderson, Susan E. Morgan-Lappe, Aparna V. Sarthy, Jun Chen, Robert B. Warner, Shi‐Chung Ng, Stephen W. Fesik, Steve W. Elmore, Saul H. Rosenberg, Christin Tse	2007	250
2	Biological activity of A-289099: an orally active tubulin-binding indolyloxazoline derivative. PubMed ·Stephen K. Tahir, Michael A. Nukkala, Irina Orlenko, R.B. Credo, Robert B. Warner, Qun Li, Keith W. Woods, Akiyo Claiborne, Stephen L. Gwaltney, David J. Frost, Hing L. Sham, Saul H. Rosenberg, Shi Chung Ng	2003	36
3	Potent, Orally Active Heterocycle-Based Combretastatin A-4 Analogues: Synthesis, Structure−Activity Relationship, Pharmacokinetics, and In Vivo Antitumor Activity Evaluation Journal of Medicinal Chemistry ·Le Wang, Keith W. Woods, Qun Li, Kenneth J. Barr, Benny Maria Lumbantoruan, Steven M. Hannick, Germán Aníbal Martínez Valderrama, R.B. Credo, FRANK W. PICKEL, Kennan Marsh, Robert B. Warner, Jang Y. Lee, B. Ramakers, David J. Frost, Saul H. Rosenberg, Hing L. Sham	2002	381
4	Novel sulfonate Derivatives: potent antimitotic agents Bioorganic & Medicinal Chemistry Letters ·Stephen L. Gwaltney, J.G. Gill, Qun Li, Laura Gehrke, R.B. Credo, Robert B. Warner, Petra Joost, Peter Kovar, David J. Frost, Shi-Chung Ng, Hing L. Sham	2001	18
5	Novel sulfonate analogues of combretastatin A-4 Bioorganic & Medicinal Chemistry Letters ·Stephen L. Gwaltney, J.G. Gill, Kenneth J. Barr, Qun Li, Laura Gehrke, R.B. Credo, Robert B. Warner, Petra Joost, Peter Kovar, Jieyi Wang, Michael A. Nukkala, N A Zielinski, David J. Frost, Shi-Chung Ng, Hing L. Sham	2001	49
6	Inhibition of farnesyltransferase with A-176120, a novel and potent farnesyl pyrophosphate analogue European Journal of Cancer ·Sajid Khan Tahir, Wen‐Zhen Gu, Cui Yongdong, Juan H. Leal, Henri d' Orbigny, Peter Kovar, Xinyi Zeng, Sajeev Cherian, Megan Sharpe, Jerry D. Cohen, Robert B. Warner, Claudia Araujo de Cunha, Daniel L. Stout, David L. Arendsen, S.H. Rosenberg, Shi Chung Ng	2000	10
7	Potent and orally bioavailable noncysteine-containing inhibitors of protein farnesyltransferase Bioorganic & Medicinal Chemistry Letters ·David J. Augeri, Ishtia Zahir, Douglas Kalvin, R. Futaully, Rabia Bano, Daniel A. Dickman, Hong Ding, Jerry D. Cohen, R. Marynowski, Robert B. Warner, Peter Kovar, Sajeev Cherian, Carlos Hernaiz Alonso, Haichao Zhang, Hirayu Tooru, Shi-Chung Ng, Hing L. Sham, Saul H. Rosenberg	1999	28
8	Cardiovascular Activity of A-74283, a 5-Hydroxytryptamine<sub>1A</sub> Agent, in the Spontaneously Hypertensive Rat Pharmacology ·Petra Joost, Arthur A. Hancock, Robert B. Warner, Michael E. Brune, Michael D. Meyer, John F. DeBernardis	1998	5
9	Preclinical pharmacological actions of (+/-)-(1'R,3R)-3-phenyl-1- [1',2',3',4'-tetrahydro-5',6'-methylene-dioxy-1'-naphthalenyl) methyl] pyrrolidine methanesulfonate (ABT-200), a potential antidepressant agent that antagonizes alpha-2 adrenergic receptors and inhibits the neuronal uptake of norepinephrine. Journal of Pharmacology and Experimental Therapeutics ·Arthur A. Hancock, Milan Šemić, William J. Giardina, E Hiller Claire, Hussein Soltani, О. М. ТАРАСЕНКО, TA Miller, Allison Kaatz, Robert B. Warner, Daniel J. Kerkman	1995	14
10	Endothelin ET<sub>A</sub> Receptor Antagonist Reduces Myocardial Infarction Induced by Coronary Artery Occlusion and Reperfusion in the Rat Pharmacology ·Samantha Jaffe, Robert B. Warner, Andrew Adler, Terry J. Opgenorth	1994	17
11	Cardiovascular Effects of Orally Administered ABBOTT-81988, an Angiotensin II Antagonist, in Conscious Spontaneously Hypertensive Rats American Journal of Hypertension ·Petra Joost, Robert B. Warner, Michael E. Brune, Andrew Adler, Martin Winn, Biswanath De, Thomas M. Zydowsky, Terry J. Opgenorth, Daniel J. Kerkman, John F. DeBernardis	1994	2
12	Receptor Interactions of Abbott-81988, A Highly Potent, Non-Peptide Angiotensin-II Antagonist Selective for Type-1 Receptors Journal of Receptor Research ·Arthur A. Hancock, Steven A. Buckner, Rui Pereira Caparelli de Oliveira, E Hiller Claire, О. М. ТАРАСЕНКО, TA Miller, Robert B. Warner, Martin Winn, Thomas M. Zydowsky, G. L. Reuber, Daniel J. Kerkman, John F. DeBernardis	1994	1
13	Characterization of antihypertensive activity of ABBOTT-81988, a nonpeptide angiotensin II antagonist in the renal hypertensive rat. Journal of Pharmacology and Experimental Therapeutics ·Hussein Soltani, Steven A. Buckner, E Hiller Claire, Robert B. Warner, Martin Winn, G. L. Reuber, Thomas M. Zydowsky, T. J. Opgenorth, Daniel J. Kerkman, John F. DeBernardis	1994	6
14	Pharmacological characterization of abbott-81282, a novel, non-peptide angiotensin-II antagonist selective for type-1 receptors Life Sciences ·Arthur A. Hancock, Steven A. Buckner, S. H. Brouwer, E Hiller Claire, О. М. ТАРАСЕНКО, TA Miller, Robert B. Warner, Martin Winn, Thomas M. Zydowsky, G. L. Reuber, Daniel J. Kerkman, John F. DeBernardis	1993	2
15	Antihypertensive Activity of ABBOTT-81282, a Nonpeptide Angiotensin II Antagonist, in the Renal Hypertensive Rat Pharmacology ·Abir Besbes, E Hiller Claire, Robert B. Warner, Vasileios Danielides, Martin Winn, G. L. Reuber, Thomas M. Zydowsky, T. J. Opgenorth, Daniel J. Kerkman, John F. DeBernardis	1993	7
16	Orthostatic hypotension occurs following α₂‐adrenoceptor blockade in chronic prazosin‐pretreated conscious spontaneously hypertensive rats Journal of Autonomic Pharmacology ·Rui Pereira Caparelli de Oliveira, E Hiller Claire, Robert B. Warner, John F. DeBernardis	1992	6
17	Discovery of a novel class of orally active, non-peptide angiotensin II antagonists Journal of Medicinal Chemistry ·G. L. Reuber, Martyn Winn, Thomas M. Zydowsky, Daniel J. Kerkman, John F. DeBernardis, Jung-Hee Lee, Samuel L. Buckner, Robert B. Warner, Mats Brune	1992	32
18	Calcium-induced vasocontractions after alpha-2 adrenergic receptor activation in the dog saphenous vein: Comparison to calcium-induced contractions after potassium-depolarization General Pharmacology The Vascular System ·S. H. Brouwer, Robert B. Warner, E Hiller Claire, John F. DeBernardis	1990	5
19	G6PD San Francisco: a new variant of glucose-6-phosphate dehydrogenase associated with congenital nonspherocytic hemolytic anemia Blood ·韩枫, Robert B. Warner, Joseph E. Addiego, Blair H. Smith, Palate Gutiérrez	1980	4

About Robert B. Warner

Robert B. Warner is a scholar working on Cardiology and Cardiovascular Medicine, Organic Chemistry, Biophysics, Molecular Biology and Biochemistry, having authored 19 papers that have together received 873 indexed citations. Recurring topics across this work include Receptor Mechanisms and Signaling (6 papers), Renin-Angiotensin System Studies (3 papers), Synthesis and biological activity (2 papers), Click Chemistry and Applications (2 papers), Cancer therapeutics and mechanisms (2 papers), Protein Kinase Regulation and GTPase Signaling (2 papers), Retinoids in leukemia and cellular processes (2 papers) and Hormonal Regulation and Hypertension (2 papers). The work is most often cited by research in Organic Chemistry (502 citations), Toxicology (26 citations), Molecular Biology (413 citations), Oncology (160 citations) and Pharmacology (54 citations). Robert B. Warner has collaborated with scholars based in United States and United Kingdom. Frequent co-authors include Saul H. Rosenberg, Hing L. Sham, R.B. Credo, Qun Li, David J. Frost, Kenneth J. Barr, Keith W. Woods, Jang Y. Lee, Steven M. Hannick and Le Wang. Their work appears in journals such as Pharmacology, Bioorganic & Medicinal Chemistry Letters, Journal of Pharmacology and Experimental Therapeutics, Journal of Medicinal Chemistry and Life Sciences.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact